Advil vs Noom
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global #1 OTC ibuprofen brand owned by Haleon (LSE/NYSE: HLN, GSK 2022 spinoff); Pfizer exited $3B+ stake early 2025 with ADA Seal for Advil Dual Action dental pain competing with Tylenol and Aleve for OTC analgesic market.
About
Advil is a global over-the-counter ibuprofen pain relief brand — owned by Haleon plc (LSE: HLN / NYSE: HLN), the consumer healthcare company spun off from GSK on July 18, 2022, with Pfizer completing its full stake exit in early 2025 for $3+ billion — providing consumers with 23+ ibuprofen-based product varieties for pain, headache, cold, and sleep management including Advil Extra Strength, Advil Rapid Release Gels, Advil PM, Advil Dual Action (ibuprofen + acetaminophen), and Children's Advil. Advil entered the US market in 1984 (the first OTC ibuprofen in America, considered the "most famous prescription-to-OTC switch in history") and generates approximately $800 million+ annually as one of Haleon's flagship brands alongside Sensodyne, Panadol, Centrum, and Theraflu. In September 2024, Advil Dual Action became the first OTC pain reliever to earn the American Dental Association (ADA) Seal of Acceptance for temporary management of acute dental pain.
Noom is a digital weight health program combining psychology-based behavioral coaching, food logging, and human coaching to help members build sustainable healthy habits.
About
Noom is a digital health company founded in 2008 that has grown into one of the most widely used weight management platforms, serving millions of members through its psychology-driven approach to behavior change. The platform combines daily lessons on cognitive behavioral techniques, food logging with a traffic-light color-coding system, personal coaching from trained health coaches, and group support to help members change their relationship with food and exercise. Noom raised over $540M and reached a $3.7B valuation, establishing it as a leading consumer digital health company. The company has expanded beyond weight loss into a broader weight health platform addressing both weight management and weight-related conditions including type 2 diabetes management with its Noom Med offering that includes GLP-1 medication prescribing. As GLP-1 medications like Ozempic and Wegovy have transformed the weight loss market, Noom has positioned its behavioral coaching as essential to sustainable results alongside medication. The platform serves both direct-to-consumer subscribers and employer health plans that offer Noom as a weight management benefit for their workforces.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.